Announced Date: 2024-11-12 (November 12, 2024) Asset Name: HEC88473 (APL-18881) Licensor: Sunshine Lake Pharma (member of … [China BD 2024] Sunshine Lake (HEC) and Apollo enters a 938 million USD License on FGF21/GLP-1 Bi-specific Fusion Protein HEC88473 (APL-18881)Read more
[China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programs
Announced Date: 2024-9-30 (September 30, 2024) Asset Name: RGT-419B(GDC-4198) and RGT-587(GDC-0587) Licensor: Regor Pharmaceuticals (China) Licensee (Buyer): … [China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programsRead more
[China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor asset
Announced Date: 2024-10-16 (October 16, 2024) Asset Name: Undisclosed Licensor (Seller): Chengdu Baiyu Pharmaceutical (China) Licensee … [China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor assetRead more
[China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46
Announced Date: 2024-10-29 (October 29, 2024) Asset Name: CMG1A46 Licensor: Chimagen Biosciences (China) Licensee (Buyer): GSK … [China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46Read more
[China BD 2024] Curon and MSD enters a 1.3 billion USD transaction for CD3xCD19-targeting TCE BiAbs CN201
Announced Date: 2024-08-07 (August 7, 2024) Asset Name: CN201 Licensor: Curon (Curon Biopharmaceutical , China) Licensee (Buyer): … [China BD 2024] Curon and MSD enters a 1.3 billion USD transaction for CD3xCD19-targeting TCE BiAbs CN201 Read more
[China BD 2024] ImmuneOnco and Instil Bio Enters a 2.05 billion USD License on two mAb Assets, PD-L1xVEGF Bispecific Antibody IMM2510 and Anti-CTLA-4 Antibody IMM27M
Announced Date: 2024-08-01 (August 1, 2024) Asset Name: IMM2510 and IMM27M Licensor: ImmuneOnco Biopharmaceuticals (Shanghai) (China) … [China BD 2024] ImmuneOnco and Instil Bio Enters a 2.05 billion USD License on two mAb Assets, PD-L1xVEGF Bispecific Antibody IMM2510 and Anti-CTLA-4 Antibody IMM27MRead more
[China BD 2024] Ascentage and Takeda enters an Option License on BCR-ABL TKI Olverembatinib
Announced Date: 2024-06-14 (June 14, 2024) Asset Name: Olverembatinib Licensor: Ascentage Pharma (China) Licensee (Buyer): Takeda … [China BD 2024] Ascentage and Takeda enters an Option License on BCR-ABL TKI OlverembatinibRead more
[China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701
Announced Date: 2024-06-13 ( June 13, 2024) Asset Name: FG-M701 Licensor: FutureGen Biopharmaceutical (Beijing) (China) Licensee (Buyer): AbbVie … [China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701Read more
[China BD 2024] Alphamab and ArriVent enters a 615.5 million USD License on two preclinical ADC assets, ARR-173 and ARR-421
Announced Date: 2024-06-05 (June 5, 2024) Asset Name: Two ADC asset （ARR-173, ARR-421） Licensor: Jiangsu Alphamab … [China BD 2024] Alphamab and ArriVent enters a 615.5 million USD License on two preclinical ADC assets, ARR-173 and ARR-421Read more
[Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products
Announced Date: 2024-05-26 (May 26, 2024) Licensor: MediLink Therapeutics (China) Licensee: BioNTech . Scope of Authority: … [Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC productsRead more